Market Overview

Regeneron Shares Fall Following BMO's Note Of Roche Preference

Related REGN
Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are down three percent following BMO analyst Jim Birchenough's note of customers cost preference of Roche's Avastin.

Birchenough remarked that there has been “broad reconsideration” of use of “low-cost” Avastin over Regeneron's Eylea by patients. The analyst noted that roughly 10 percent of Eylea patients at an investigator's clinic are being switched back to Avastin.

BMO reported that there has been increased inquiry into brand anti-VEGF therapy over Avastin, with “brand therapy becoming harder to justify for stable patients with lower visual acuity.”

Shares of Regeneron closed at $297.69 on Thursday. The stock fell as much as 5.1 percent to $282.52 in Friday's morning trading.

Latest Ratings for REGN

DateFirmActionFromTo
Sep 2014Credit SuisseMaintainsOutperform
Sep 2014Brean CapitalMaintainsBuy
Aug 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: BMO Jim BirchenoughAnalyst Color Short Ideas Analyst Ratings Trading Ideas

 

Related Articles (REGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional